Evidence map›Paper›PMID 39485557›Full record

ArticleClinical and experimental medicine2024

Early minimal residual disease eradication in light chain amyloidosis generates deeper and faster cardiac response.

Tianhong Xu, Jing Li, Yang Yang, Wenjing Wang, Chi Zhou, Pu Wang, Chenqi Yu, Peng Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tianhong Xu *Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, China.
Jing Li *Department of Hematology, Zhongshan Hospital Fudan University, Shanghai, China.
Yang YangDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, China.
Wenjing WangDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, China.
Chi ZhouDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, China.
Pu WangDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, China.
Chenqi YuDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, China.
Peng LiuDepartment of Hematology, Zhongshan Hospital Fudan University, Shanghai, China. liu.peng@zs-hospital.sh.cn.

Funding

Natural Science Foundation of Shanghai 22ZR1411400
6 · The paper itself

Abstract

Minimal residual disease (MRD) is of growing interest in light chain (AL) amyloidosis and is associated with higher rates of cardiac response. A new graded cardiac response criteria has been proposed for better assessment of cardiac improvement. We evaluated MRD status in 63 patients with cardiac AL amyloidosis using next generation flow cytometry (sensitivity ≥ 1*10

Indexed as

Immunoglobulin Light-chain AmyloidosisNeoplasm, ResidualAdultAgedAged, 80 and overBortezomibFemaleFlow CytometryHumansMaleMiddle AgedProteasome InhibitorsTreatment OutcomeBortezomibProteasome InhibitorsCardiacLight chain amyloidosisMinimal residual disease

Identifiers

PMID39485557
PMCPMC11530485

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.